

Janus Kinase (JAK) Inhibitors - Competitive Landscape, Technology and Pipeline Analysis, 2017

<https://marketpublishers.com/r/JC42949727DEN.html>

Date: November 2017

Pages: 323

Price: US\$ 2,450.00 (Single User License)

ID: JC42949727DEN

Abstracts

This report can be delivered to the clients within 24 Hours

DelveInsight's, "Janus Kinase (JAK) Inhibitors- Competitive Landscape, Pipeline and Market Analysis, 2017", report provides comprehensive insights about marketed and pipeline drugs across this Mechanism of action. Key objective of the report is to establish the understanding for all the marketed and pipeline drugs that fall under Janus Kinase (JAK) Inhibitors. This report provides information on the therapeutic development based on Janus Kinase (JAK) Inhibitors mechanism of action dealing with around 35+ active pipeline drugs. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. Report contains the development and sale activities for marketed drugs. DelveInsight's Report also assesses the Janus Kinase (JAK) Inhibitors therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration. The report also covers the information for 25+ active companies involved in the therapeutic development of the products.

SCOPE

The report provides competitive pipeline landscape of Janus Kinase (JAK) Inhibitors

The report provides the marketed drugs information including its sales, development activities and details of patent expiry

The report provides the insight of current and future market for Janus Kinase

(JAK) Inhibitors

The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information

Coverage of the Janus Kinase (JAK) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

The report reviews key players involved in the therapeutics development for Janus Kinase (JAK) Inhibitors and also provide company profiling

The report also gives the information of dormant pipeline projects

Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages

Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

REASONS TO BUY

Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage

Complete MOA intelligence and complete understanding over therapeutics development for Janus Kinase (JAK) Inhibitors

Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.

Devise corrective measures for pipeline projects by understanding Janus Kinase (JAK) Inhibitors pipeline depth and focus of Indication therapeutics

Developing strategic initiatives to support your drug development activities.

Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business.

Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

Contents

- Introduction
- Executive Summary
- Executive Summary Snapshot
- Janus kinase Inhibitors (JAK Inhibitors) Overview
- Introduction
- Structure and Mechanism
- Janus Kinase Inhibitors
- Types of JAK Inhibitors
- Cytokines associated with Janus kinases and result of their mutations
- JAK Inhibitors Market Analysis
- Collaborations and Deals
- Acquisition Deals
- Designations Analysis
- Grants
- Financing
- Companies Involved in JAK Inhibitor Development
- Therapeutic Targets by Company and Indication
- Market Drivers and Barriers
- Drivers
- Barriers
- Marketed Products
- Therapeutics under Development by Companies
- Late Stage Products (Filed &Phase III)
- Comparative Analysis
- Mid Stage Products (Phase II)
- Comparative Analysis
- Early Stage Products (Phase I and IND)
- Comparative Analysis
- Discovery and Pre-clinical stage Products
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Monotherapy Products
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Dormant Products

Companies involved in Therapeutics Development

Upcoming Conferences

SWOT Analysis for JAK Inhibitors

Appendix

Methodology

Consulting Services

About DelveInsight

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

- Table 1: Collaboration and Deal Values for JAK Inhibitors, 2017
- Table 2: Acquisition deals for the development of JAK Inhibitors, 2017
- Table 3: Grants, 2017
- Table 4: Number of Products Under Development for Janus Kinase (JAK) Inhibitors, 2017
- Table 5: Number of Products under Development by Companies, 2017
- Table 6: Late Stage Products (Filed & Phase III), 2017
- Table 7: Mid Stage Products (Phase II), 2017
- Table 8: Early Stage Products (Phase I and IND), 2017
- Table 9: Discovery and Pre-clinical stage Products, 2017
- Table 10: Assessment by Monotherapy Products, 2017
- Table 11: Assessment by Route Of Administration, 2017
- Table 12: Assessment by Stage and Route Of Administration, 2017
- Table 13: Assessment by Molecule Type, 2017
- Table 14: Assessment by Stage and Molecule Type, 2017
- Table 15: Dormant Products, 2017
- Table 16: Discontinued Products, 2017
- Table 17: AbbVie, Overview, 2017
- Table 18: Aclaris Therapeutics, Inc., Overview, 2017
- Table 19: Advinus Therapeutics, Overview, 2017
- Table 20: Amgen Inc., Overview, 2017
- Table 21: Aptose Biosciences, Overview, 2017
- Table 22: Arrien Pharmaceuticals, Overview, 2017
- Table 23: Asana BioSciences, Overview, 2017
- Table 24: Astellas Pharma Inc., Overview, 2017
- Table 25: Astrazeneca, Overview, 2017
- Table 26: Bristol-Myers Squibb, Overview, 2017
- Table 27: CleveXel Pharma, Overview, 2017
- Table 28: Cloud pharmaceuticals, Overview, 2017
- Table 29: Concert Pharmaceuticals, Overview, 2017
- Table 30: CTI BioPharma, Overview, 2017
- Table 31: Cytopia Research, Overview, 2017
- Table 32: Eli Lilly and Company, Overview, 2017
- Table 33: Galapagos NV, Overview, 2017
- Table 34: Gilead Sciences, Overview, 2017

- Table 35: Hoffmann-La Roche, Overview, 2017
- Table 36: Incyte Corporation, Overview, 2017
- Table 37: Japan Tobacco Company, Overview, 2017
- Table 38: Nimbus Therapeutics, Overview, 2017
- Table 39: Pfizer Inc., Overview, 2017
- Table 40: Portola Pharmaceuticals, Overview, 2017
- Table 41: Sareum Limited, Overview, 2017
- Table 42: Theravance Biopharma, Overview, 2017
- Table 43: Tragara Pharmaceuticals, Overview, 2017
- Table 44: Vectura Group, Overview, 2017

List Of Figures

LIST OF FIGURES

- Figure 1: Structure of Janus Kinase
- Figure 2: Illustrated mechanism of Janus Kinase
- Figure 3: Collaboration and Deals for JAK Inhibitors, 2017
- Figure 4: Number of Companies under acquisition for JAK Inhibitors, 2017
- Figure 5: Designation Analysis for JAK Inhibitors, 2017
- Figure 6: Grants, 2017
- Figure 7: Number of Products under Development for JAK Inhibitor, 2017
- Figure 8: Number of Products under Development for Janus Kinase(JAK) Inhibitors, 2017
- Figure 9: Late Stage Products (Filed &Phase III),2017
- Figure 10: Mid Stage Products (Phase II),2017
- Figure 11:Early Stage Products (Phase I and IND), 2017
- Figure 12: Discovery and Pre-clinical stage Products, 2017
- Figure 13: Number of Products under Development for JAK Inhibitors,2017
- Figure 14: Assessment by Route of Administration, 2017
- Figure 15: Assessment by Stage and Route of Administration,2017
- Figure 16: Assessment by Molecule Type,2017
- Figure 17: Assessment by Stage and Molecule Type,2017
- Figure 18: Dormant Products, 2017
- Figure 19:Discontinued Products, 2017

I would like to order

Product name: Janus Kinase (JAK) Inhibitors - Competitive Landscape, Technology and Pipeline Analysis, 2017

Product link: <https://marketpublishers.com/r/JC42949727DEN.html>

Price: US\$ 2,450.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/JC42949727DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

